Mehanizam dejstva, efikasnost i bezbednost hitne hormonske kontracepcije (levonorgestrela i ulipristal acetata) i stavovi farmaceuta by Milosavljević, Jelena et al.
  155
 
Scientific Journal of the Faculty of Medicine in Niš 2014;31(3):155-161 
 







Jelena Milosavljević1, Katarina Ilić2, Dušanka Krajnović1,3 
 
1University of Belgrade, Faculty of Pharmacy, Department of Social Pharmacy and Pharmaceutical Legi-
slation, Serbia 
2University of Belgrade, Faculty of Pharmacy, Department of Pharmacology, Serbia 









Emergency hormonal contraception is used to prevent unintended pregnancy postco-
itally. The mechanism of action of the most frequently used hormonal preparations for emer-
gency contraception, levonorgestrel (LNG) and ulipristal acetate (UPA), is still not fully known, 
but clinical trials indicate that they act by inhibiting or delaying ovulation. LNG has a long 
history of use for emergency contraception, proven safety and high efficacy if administered 
in the preovulation period. The newest emergency contraceptive, UPA, available only with a 
prescription, is indicated within this period of 120 hours after sexual intercourse and the 
data indicate that UPA does not lose efficacy within this period. Clinical trials showed its non-
inferiority versus LNG and its effect on the potentially occurring pregnancy is being additio-
nally monitored. However, many misconceptions and controversial opinions about emergency 
contraception are still present, even among pharmacists. A search of Medline database iden-
tified 20 papers published from January 1993 to December 2012, on pharmacists’ know-
ledge, attitudes and practices related to emergency contraception. In these papers, the atti-
tudes of pharmacists pertaining to the dispensing regime of emergency contraception were 
different. Research in Australia has shown that personal attitudes and religious convictions 
influence the practice of dispensing emergency contraception. In the research conducted in 
New Mexico, 30% of pharmacists were against prescribing emergency contraception for reli-
gious or moral reasons. There were no published data in regards to pharmacists’ knowledge, 
attitudes and dispensing practice in Serbia and such research is highly recommended.   
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Emergency hormonal contraception is administe-
red with the goal to prevent unintended pregnancy after 
unprotected sexual intercourse or missed/unsuccessfully 
administered regular method of contraception. Emer-
gency hormonal contraception prevents fertilization and 
thus is not an abortifacient, as according to medical cri-
teria pregnancy begins with the implantation of the ferti-
lized ovum (1). The Yuzpe method was named after a 
Canadian gynecologist who was the first to administer in 
the 1970s a combination of 250 μg levonorgestrel (LNG) 
and 50 μg ethynil estradiol in two doses as emergency 
hormonal contraception. Today, this method is less frequ-
ently used because levonergestrel only based emergen-
cy contraception is more efficient and because estrogen 
component more often leads to adverse effects, primari-
ly nausea, headache and painful breast tenderness (2). 
In the 1990s, two doses of LNG of 0.75 mg began to 
be applied for emergency contraception, which proved 
to be a more efficient and safer method than Yuzpe’s; 
nausea appears in approximately 16% of cases vs. 46% 
and vomiting in 2.7% vs. 22.4% (3). There are two ty-
pes of LNG preparations; with 0.75 mg LNG in the case 
of which the first tablet is taken within the interval of 72 
hours of sexual intercourse, and the second 12 hours 
later, and LNG with 1.5 mg LNG which is administered 
as a single dose, which is more practical. Because of its 
proven safety and high efficacy, LNG is regarded as the 
“golden standard” of emergency contraception (4). In 
certain countries, e.g. China and Israel, mifepristone, a 
competitive progesterone antagonist, is also used for 
emergency contraception. However, in most countries, 
mifepristone use led to great social problems, because 
in higher doses it used to induce medicament abortion 
(5). The latest preparation belonging to this group, uli-
pristal acetate (UPA), was approved for use in Europe in 
2009, and in 2010 in the United States of America 
(USA) and Serbia. It is indicated within 120 hours after 
sexual intercourse, and clinical trials showed its non-
inferiority versus LNG (6). 
Today, preparations for emergency contraception 
are available in over 140 countries (7). Broader admini-
stration of emergency contraception prevents numerous 
abortions, thus users have direct access to LNG tablets 
in nine countries (Bangladesh, Bulgaria, Canada, India, 
Laos, the Netherlands, Norway, Sweden and the USA). 
In over 60 countries,  pharmacist can dispense LNG with-
out prescription (e.g. in Australia, Austria, Great Britain, 
Spain, Slovenia, Serbia, Bulgaria, and others) (7). No 
matter if emergency contraception is obtained with or 
without prescription, pharmacists can considerably influ-
ence the scope and adequate use of these prepara-
tions. However, moral, ethical or religious convictions of 
the pharmacist can oppose the use of emergency con-
traception. Thus, in some countries, as in the USA, phar-
macist can refuse to dispense emergency contraception 
to the users (8). In such cases, the pharmacist must act 
professionally and as soon as possible, without conde-
mning, direct the user to another pharmacist who will 
dispense her emergency contraception. These pharma-
cists should also timely inform their colleagues and em-




The aim of this paper was to review the practice, 
knowledge and attitudes of pharmacists pertaining to 
emergency hormonal contraception as well as the latest 
data on the mechanism of action, efficacy and safety of 
the most frequently used emergency hormonal contra-
ceptives, LNG and UPA.  
 
MATERIAL  AND METHODS 
 
From January to March 2013, Medline database 
was searched to find papers published from January 
1993 to December 2012, presenting data pertaining to 
knowledge, attitudes and practice of pharmacists in con-
nection with the dispensing and use of emergency hor-
monal contraception. Papers published in Serbian and 
English were taken into consideration. The following key 
words and Mesh terms were used for the search: con-
traception, postcoital, emergency contraception, contra-
ceptives, contraceptive agents, pharmacist, pharmacy, 
knowledge, attitudes, practice. Papers from the obtai-
ned list were reviewed. In addition, references were revi-
ewed and additional papers were included.  
 
RESULTS AND DISCUSSION 
 
Mechanism of  act ion  and t ime  
o f  admin is t rat ion  of  emergency  
cont racept ion  
Levonorgrestrel 
The exact mechanism of action of LNG is not fully 
known, but it is believed that LNG inhibits or delays ovu-
lation, i.e. the effect of LNG postpones the development 
and maturation of follicles, inhibits rupture and  forma-
tion of the persistent follicle. If it is administered before 
the level of the luteinizing hormone (LH) begins to rise in 
mid-cycle, the process of ovulation can be inhibited or 
delayed for the next 5-7 days, which is a sufficiently 
long period for spermatozoa present in the female geni-
tal tract to become inactive (9). If the LNG tablet is ad-
ministered closer to the time of ovulation, prevention of 
ovulation is less probable. It has been established that 
LNG has no effect if administered immediately before 
ovulation, and it is also considered to be ineffective after 
fertilization (10). Clinical trials confirmed that LNG does 
not influence the process of implantation of the embryo 
in the endometrium, nor has any significant effect been 
noted on oviduct motility (11).  
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Ulipristal acetate 
UPA is a synthetic selective progesterone recep-
tor modulator with a high binding affinity that thus pre-
vents or delays ovulation (12). Clinical trials have shown 
that in over 60% of women UPA administration led to 
delay of ovulation by a minimum of 5 days (13). UPA 
efficacy depends on the time of administration; if it is 
administered before the level of LH begins to rise, ovula-
tion is postponed by a minimum of 5 days in 100% of 
subjects. If UPA is administered in the rising phase, but 
before the LH peak is reached, in 78.6% of women ovu-
lation is postponed by minimum 5 days. However, if it is 
administered after the LH peak is reached, ovulation is 
postponed in 8.3% of women (14, 15). It was shown 
that UPA also leads to changes in the endometrium, but 
it is still not clear if this causes inhibition of implantation 
(16), thus it is considered that the activity of UPA is pri-
marily based on delaying of ovulation.  
 
Ef f icacy  and safety  
 
One of the proposed parameters for determining 
the efficacy of emergency contraception is the so-called 
prevented fraction, obtained by subtracting the quotient 
between the number of registered pregnancies after the 
administration of emergency contraception and the num-
ber of pregnancies without the use of emergency con-
traception. The prevented fraction is the number of pre-
gnancies avoided by administering emergency contra-
ception (17). In evaluation of efficacy of EC there are 
many problems such as the exact time of ovulation, 
which is often not known, some women do not recall 
when they had the last menstrual cycle and/or when the 
unprotected intercource occured, whereas some women 
are already pregnant when emergency contraception is 
administered. The fertile ability of concerned woman 
and man is unknown as well.  Using the same evaluati-
on method that was used for LNG and UC made com-
parison of their efficacy  possible. 
LNG is efficient if it is administered within the first 
72 hours after sexual intercourse, but it is still unclear if 
its efficacy declines during this time interval. Analysis of 
results of four randomized trials performed by the World 
Health Organization (WHO) established that there is no  
statistically significant difference in the rates of preg-
nancy after the administration of LNG on days 2, 3 or 4, 
compared to day 1 (18). It has also been proven that 
the efficiency of UPA does not decline if it is administe-
red after a longer period of time after sexual intercourse 
if 120 hours have not lapsed (6, 19). In the  meta-
analysis that compared the efficiency of UPA and LNG, 
depending on the time of administration within the in-
terval between 0 and 120 hours, Glasier et al. showed 
that the pregnancy rate was statistically significantly 
lower in the group of women who used UPA compared 
to LNG (Table 1) (6).  
After the administration of LNG and UPA there 
was no statistically significant difference in the type and 
frequency of adverse reactions (Table 2) (6). After LNG 
administration slightly under 20% of women experien-
ced nausea, whereas vomiting occurred in only 1% of 
users (20). When dispensing emergency contraception 
it is important to counsel users about repeating the do-
se of the preparation if vomiting occurs within three ho-
urs after administration (12, 21). In addition, users sho-
uld be informed about the possibility of a transient dis-
turbance of the rhythm of menstrual bleeding. However, 
if no bleeding appears within three weeks after using 
emergency contraception, or if menstruation is late by 
more than a week, users should be advised to take a 
pregnancy test (22).  
It is regarded that administration of repeated LNG 
doses is safe and efficient, so that it can also be used 
more than once during one cycle (23). As opposed to 
LNG, UPA should not be used more than once during 
one menstrual cycle (12).  
The few data obtained from epidemiological stu-
dies have not indicated that LNG had any harmful effect 
on the fetus if pregnancy occurs in spite of the admini-
stration of emergency hormonal contraception (21). How-
ever, it is not known how UPA influences the course and 
outcome of pregnancy. Since this is a rather new prepa-
ration for emergency contraception, its adverse reacti-
ons are carefully monitored. There is a European Regi-
ster for monitoring pregnancy outcome in women who 
had used UPA. Patients and healthcare professionals 
should be encouraged to report all cases of adverse re-
actions caused by UPA administration (12).  
 
Table 1. Meta-analysis of efficacy of ulipristal acetate and levonorgestrel (6) 
Pregnancies, n/N (%) Time (hours) from 
unprotected sexual 
intercourse to intake of 




0-24 5/584 (0,9%) 15/600 (2,5%) 0,35 (0,11 - 0,93) 0,035 
0-72 22/1617 (1,4%) 35/1625 (2,2%) 0,58 (0,33 - 0,99) 0,046 
0-120 22/1714 (1,3%) 38/1731 (2,2%) 0,55 (0,32 - 0,93) 0,025 
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Table 2. Frequency of adverse reactions in levonorgestrel and ulipristal acetate users (6) 
LNG users UPA users 
Adverse reaction 
n % n % 
Headache 211 18,9 213 19,3 
Dysmenorrhoea 160 14,3 142 12,9 
Nausea 126 11,3 141 12,8 
Fatigue 44 3,9 61 5,5 
Dizziness 55 4,9 57 5,2 
Abdominal pain 75 6,7 56 5,1 
Upper abdominal pain 46 4,1 37 3,3 
Back pain 27 2,4 35 3,2 
 
 
Knowledge,  at t i tudes and 
pract ice of  pharmac is ts  
regard ing emergency  
cont racept ion  
 
We identified 20 papers on the pharmacists’ 
knowledge, attitudes and practice in regards to emer-
gency contraception, and considerable differences were 
not found. For example, in a research performed in 1997 
in South Africa, 69% of pharmacists support the dispen-
sing of emergency contraception without prescription, 
while 67% believe that this is important for increasing 
the level of public awareness about this type of preven-
tion of unintended pregnancy (24). On the contrary, the 
research performed by Barett and Harper in 1996 in 
Great Britain among pharmacists in public pharmacies 
and general practitioners revealed a negative attitude 
regarding the regime of dispensing these medicines 
without prescription (25). Research performed in Swe-
den in 2002 showed that 70% (153) of pharmacists 
and 68% (91) of physicians considered that it is indi-
spensable to establish adequate cooperation between 
pharmacies and clinics on the issue of emergency con-
traception. Pharmacists need advice and support of ex-
perienced professionals, especially in cases pertaining 
to teenagers. Physicians feel that pharmacists should 
offer users adequate information about local clinics that 
can further monitor and counsel them, and in specific 
cases refer patients to them (26). Personal attitudes and 
religious beliefs of pharmacists can influence their prac-
tice. Research performed in Australia from December 
2008 to January 2009 showed that 22% (92/418) of 
pharmacists from public pharmacies considered reaso-
nable that religious beliefs of the pharmacists influence 
their decision to dispense emergency contraception. In 
this research, 75.1% of pharmacists occasionally refu-
sed to dispense emergency contraception most frequen- 
 
tly because someone else came to the pharmacy in-
stead of the intended user (59.7%), the user was under 
16 years of age (35.1%), and more than 72 hours had 
passed after unprotected sexual intercourse (30%). Ad-
vanced provision of emergency contraception to any wo-
men under any circumstances was unacceptable for 
69% of pharmacist, to parents of intended users for 
63.9% of pharmacists and users under 16 years of age 
for 71.7% of pharmacists. Of the total number of inter-
viewed pharmacists, 65.2% had training for counseling 
relevant to dispensing emergency contraception. Phar-
macists most often counseled users about the dosage 
(91.8%), adverse reactions (90.2%), and efficacy of 
emergency contraception depending on the time lapsed 
from unprotected sexual intercourse to the time of ad-
ministering emergency contraception (88.8%). Among 
interviewed pharmacists 81.9% agreed that when dis-
pensing emergency contraception, it is their task to co-
unsel the user about regular contraception, but only 
54.5% felt that users should also be offered advice 
about sexually transmissible infections. Pharmacists in 
this research stated that the lack of privacy was a ba-
rrier for adequate counseling the user. Many stated that 
they counseled users only in isolated parts of the phar-
macy where it was possible to provide privacy or in a 
place at a distance from other patients (27). Research 
performed in Turkey in 2008 showed that 98% (539/ 
551) of pharmacists had experience with dispensing 
emergency contraception, and 70% stated that they 
occasionally dispense it also to men. Generally, most 
pharmacists had a positive attitude toward the existence 
of emergency contraception and felt that its use is  
ethical. To the question if their pharmacy had a space 
for counseling where privacy is secured, 75% answered 
affirmatively, 80% of female pharmacists and 66% of 
male pharmacists. At the same time, 79% confirmed 
that they feel comfortable to offer advice on contracep-
tion, while 16% stated that they were comfortable only if 
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the patient was of the same sex. Advice most frequently 
offered by pharmacists in Turkey pertained to the time 
period when tablets are taken (89%), dosage (86%), 
efficacy (73%), pregnancy test (63%), adverse reactions 
(50%) and methods of contraception (48%). The main 
sources of information about emergency contraception 
for pharmacists were representatives of pharmaceutical 
companies (53%) and continuous education programs 
(26%). It is presumed that female pharmacists know 
more about emergency contraception from personal ex-
perience, so they offer advice more often, and feel more 
comfortable during the process than men. Because of 
cultural influences in Turkey, certain male pharmacists 
did not feel comfortable when offering advice on emer-
gency contraception. Pharmacists in this research were 
generally against dispensing emergency contraception 
with a prescription only, while 58% felt that the dispen-
sing of emergency contraception should be limited only 
to persons over 18 years of age (28). 
According to the results of research conducted among  
523 pharmacists in New Mexico in 2004, the main cha-
llenges that pharmacists had to overcome in their prac-
tice when dispensing emergency contraception were: 
the lack of insight into the patient medical history, no 
follow-up on efficacy of emergency contraception, lack 
of time and lack of a private space for counseling. Some 
30% of pharmacists in this research were against pres-
cribing emergency contraception for religious or moral 
reasons. Almost 25% of responders agreed with the sta-
tement that emergency contraception is a form of abor-
tion. As opposed to 76% of pharmacists who stated that 
they would refer patient to another pharmacist who wo-
uld provide emergency contraception if their employer 
would not permit them to dispense it themselves, 24% 
of pharmacists would not provide it or refer the patient 
to another pharmacist. Results of this research additio-
nally strengthened the debate pertaining to the right of a 
pharmacist to refuse to dispense emergency contracep-
tion with moral objection (29). 
There were not published data on the pharma-
cists knowledge, attitudes and dispensing practice in 
Serbia and such research will be of a high interest for 
medical professionals, emergency contraceptive users 
and reproductive health of women in Serbia. In pharma-
cies in Serbia both most popular preparations for emer-
gency contraception, LNG and UPA, are available. LNG 
is dispensed without prescription to users over 16 years 
of age, while LNG use is not recommended for users un-
der 16 years of age without medical supervision (21).  
UPA is dispensed only with a prescription (12). There is 
no published data how often pharmacists in Serbia dis-
pense emergency contraception, if they provide coun-
seling. Often frequent users of emergency contraception 
are teenagers and young nulipara women whose re-
productive health should be protected. Considering the 
fact that one of emergency contraception preparation is 
available without prescription, pharmacists are the only 
ones who are in contact with the users, so thus their 




Emergency contraception is a second chance for 
women to prevent pregnancy at the time when regular 
contraception fails, or when it is not used. Efficacy and 
safety of LNG has been demonstrated during many ye-
ars of use. In addition, there is a new product, UPA, that 
proved in clinical trials to be at least as effective as LNG, 
and whose influence on a potential pregnancy is still be-
ing monitored. Since pharmacists are the healthcare 
professionals most accessible to users, their role is of 
key importance for adequate administration of these pro-
ducts. However, from investigations in other countries it 
is evident that the knowledge and personal attitudes of 
pharmacists can influence their practice when dispen-
sing emergency contraception and sometimes also lead 
to users being denied the preparation. There is no pu-
blished data about the status in Serbia relevant to this 
issue. Therefore, the recommendation is to conduct re-
search about the knowledge, attitudes and practices of 
pharmacists regarding emergency hormonal contracep-
tion.  
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Saže tak  
 
Hitna hormonska kontracepcija se koristi za sprečavanje neželjene trudnoće postkoitalno. Mehani-
zam dejstva najčešće korišćenih preparata hitne kontracepcije, levonorgestrela (LNG) i ulipristal-acetata 
(UPA) još uvek nije u potpnosti poznat, ali klinička ispitivanja ukazuju da je u pitanju inhibicija ili odlaganje 
ovulacije. Za hitnu kontracepciju dugo se koristi LNG, jer ima dokazanu bezbednost i visoku efikasnost, 
ukoliko se primeni u periodu pre ovulacije. Najnoviji preparat iz ove grupe, UPA, koji se izdaje samo na re-
cept, može se primeniti u periodu od 120 sati nakon seksualnog odnosa. U kliničkim ispitivanjima se nije 
pokazao lošijim u odnosu na LNG, a njegov uticaj na eventualno nastalu trudnoću se dodatno prati. Podaci 
ukazuju na činjenicu da UPA ne gubi na efikasnosti u periodu od 120 sati. Međutim, prisutne su mnoge 
zablude i kontroverzna mišljenja o hitnoj kontracepciji, čak i među farmaceutima. Pretraživanjem Medline 
baze podataka nađeno je 20 radova objavljenih u periodu od januara 1993. do decembra 2012. godine koji 
razmatraju znanje, stavove i praksu farmaceuta u vezi sa hitnom kontracepcijom. U ovim radovima se sta-
vovi farmaceuta razlikuju po pitanju režima izdavanja hitne kontracepcije. Istraživanje u Australiji pokazalo 
je da lični stavovi i religijska uverenja utiču na način izdavanja hitne kontracepcije. U istraživanju u Novom 
Meksiku 30% farmaceuta je bilo protiv propisivanja hitne kontracepcije iz religioznih ili moralnih razloga. 
Među pronađenim radovima nije bilo podataka o istraživanjima iz Srbije. Preporuka je da se sprovedu istra-
živanja o znanju, stavovima i praksi farmaceuta u vezi sa hitnom hormonskom kontracepcijom u Srbiji. 
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